MedTrace Logo

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

NCT02868385 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2020-11-18

No results posted yet for this study

Summary

An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire

This study aims to determine the efficacy of repeated (up to four times) praziquantel treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive antigen- and DNA-detection methods.

Conditions

  • Schistosomiasis

Interventions

DRUG

4x Praziquantel

Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.

DRUG

1x Praziquantel

One praziquantel treatment (40 mg/kg) at baseline

Sponsors & Collaborators

  • Swiss Tropical & Public Health Institute

    collaborator OTHER

  • Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

    collaborator OTHER

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Jean Coulibaly · Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-01-14
Completion
2019-01-14

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868385 on ClinicalTrials.gov